{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000051","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.310844+00:00","generated_at":"2026-06-01T01:17:45.010211+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Partner Verona Pharma gets FDA approval for Ohtuvayre (COPD); Ligand earns $5.8M milestone, $13.8M at launch","bullets":["FDA approved Ohtuvayre (ensifentrine) for maintenance treatment of COPD in adults; first novel inhaled mechanism in over 20 years.","Ligand earned a $5.8 million milestone payment; additional $13.8 million due upon commercial launch expected in Q3 2024.","Ligand is entitled to a low single-digit royalty on potential worldwide net sales of Ohtuvayre; COPD market is multi-billion dollar.","Verona Pharma is responsible for commercialization; Ligand relies on Verona for successful launch and sales.","Approval triggers immediate milestone and sets stage for further payments and ongoing royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000051","json":"https://secwatch.observer/filing/0000886163-24-000051.json","markdown":"https://secwatch.observer/filing/0000886163-24-000051.md","text":"https://secwatch.observer/filing/0000886163-24-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000051/0000886163-24-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000051/lgnd-20240627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:17:45.010211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}